Skip to search formSkip to main contentSkip to account menu

MVA 85A

Known as: MVA-85A, MVA85A 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (2)

AERAS 485MVA AG85A

Broader (1)

Tuberculosis Vaccines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy.
2015
2015
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
Background MVA85A and AERAS-402 are two clinically advanced viral vectored TB vaccine candidates expressing Mycobacterium… 
Review
2014
Review
2014
A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data☆
Highly Cited
2014
Highly Cited
2014
The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses
Background Vaccination against tuberculosis (TB) should provide long-term protective immunity against Mycobacterium tuberculosis… 
Review
2013
Review
2013
Vaccine Development for Tuberculosis: Current Progress
Very substantial efforts have been made over the past decade or more to develop vaccines against tuberculosis. Historically, this… 
Review
2013
Review
2013
Vaccination against tuberculosis: how can we better BCG?
Highly Cited
2012
Highly Cited
2012
A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.
RATIONALE Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis… 
Highly Cited
2011
Highly Cited
2011
Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
BACKGROUND BCG, the only licensed tuberculosis vaccine, affords poor protection against lung tuberculosis in infants and children… 
Highly Cited
2008
Highly Cited
2008
In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination
Adjuvants are substances that enhance immune responses and thus improve the efficacy of vaccination. Few adjuvants are available… 
Highly Cited
2008
Highly Cited
2008
Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
Background Vaccination with a recombinant modified vaccinia Ankara expressing antigen 85A from Mycobacterium tuberculosis, MVA85A… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)